Clinical Trial: The Rationale to Conduct This RWE Study is to Provide Data to Support the Safety of CD34 Selected Grafts Versus T Replete PBSC Transplants to Address Concerns About Increased TRM in CD34 Selected Graft Recipients.

U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07717164) titled 'The Rationale to Conduct This RWE Study is to Provide Data to Support the Safety of CD34 Selected Grafts Versus T Replete PBSC Transplants to Address Concerns About Increased TRM in CD34 Selected Graft Recipients.' on July 16.

Brief Summary: The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.

Study Start Date: July 31

Study Type: OBSERVATIONAL

Condition: ALL (Acute B-Lymphoblastic Leukemia) AML (Acute Myeloid Leukemia) MDS (Myelodysplastic Syndrome)

Recruitment Status:...